LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled "Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier ...

分组1 - Voyager Therapeutics reported a quarterly loss of $0.53 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and compared to a loss of $0.20 per share a year ago, indicating an earnings surprise of -51.43% [1] - The company posted revenues of $6.47 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 66.26%, and down from $19.52 million in the same quarter last year [2] - Voyager Therapeutics shares have declined approximately 38.5% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.31 on revenues of $19.19 million, and for the current fiscal year, it is -$1.41 on revenues of $90.91 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-3003182 ( ...

EXHIBIT 99.1 Voyager Reports First Quarter 2025 Financial and Operating Results - Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg - - Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer's disease - LEXINGTON, Mass., May 6, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a bio ...

LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported first quarter 2025 financial and operating results. "Voyager ended the first quarter of 2025 with a strong cash position of $295 million, which we expect to provide runway into mid-2027. This runway guidance does not include potential milestone payments from existing partnerships, such as the up to $35 million we ...

- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti-amyloid gene therapy for Alzheimer’s disease, as well as multiple presentations on Voyager’s continued enhancements to its highly BBB penetrant novel capsids - LEXINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to lev ...

- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - Dr. Ferguson will be speaking on two panels at AD/PD™ 2025: Challenges and Opportunities for Anti-Tau Therapi ...

Financial Data and Key Metrics Changes - The company reported $332 million in cash as of the end of 2024, with $8.2 billion in potential future milestone payments expected to contribute significantly to the bottom line [9][10]. - Developmental milestones amount to $2.9 billion, with total potential milestones exceeding $8 billion, providing a significant upside to the mid-2027 cash runway guidance [28][30]. Business Line Data and Key Metrics Changes - The SOD1 silencing gene therapy program has moved back into the research stage due to the payload not meeting target profiles, while the VY1706 tau silencing gene therapy has advanced into IND-enabling studies [14][15]. - The anti-tau antibody, VY7523, showed promising results in a single ascending dose study, with no serious adverse events reported and a CSF to serum ratio of 0.3% [16][17]. Market Data and Key Metrics Changes - The company is focusing on the tau target in Alzheimer's disease, which is viewed as critical, with multiple upcoming data readouts expected to generate excitement in the market [8][18]. - The recent data from UCB's bepranemab indicated that an anti-tau antibody can impact tau accumulation in the human brain, although it did not meet its primary endpoint [17][18]. Company Strategy and Development Direction - The company aims to build a multimodal neuro-therapeutics platform, emphasizing gene therapy as a key component of its pipeline [11][12]. - Partnerships have been a significant source of non-dilutive revenue, and the company remains open to additional business opportunities [10][11]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of their IV-delivered AAV capsids to efficiently deliver therapies across the blood-brain barrier, which is critical for treating CNS diseases [13][18]. - The management acknowledged the challenges in the gene therapy field but emphasized the importance of focusing on genetically validated targets in severe diseases with high unmet needs [11][12]. Other Important Information - The company is preparing to share data from its non-human primate studies, which showed a 50% to 73% knockdown of tau mRNA across the brain [16][17]. - The company is also exploring the applicability of its ALPL-based non-viral shuttle for various diseases, including spinal cord and cerebral cortex conditions [37][39]. Q&A Session Summary Question: Insights on upcoming data at ADPD - Management anticipates data from bepranemab regarding exposure PD relationships and the necessary decrease in tau spreading for clinical relevance [22][24]. Question: Upcoming milestones from partnered programs - The company has $2.9 billion in developmental milestones, with additional upside to the mid-2027 cash runway guidance [28][30]. Question: Details on tau gene silencing IND - The main requirement is completing the GLP tox study and ensuring a therapeutic window [35]. Question: Applications of the ALPL shuttle - The ALPL shuttle is being assessed for various diseases, with potential for transporting proteins, antibodies, and oligonucleotides [37][39]. Question: Differences between tau silencing and antibody approaches - The knockdown approach may allow for broader tau knockdown and is administered via IV, which could be more beneficial for patients [45][46]. Question: Proof of concept for SOD1 gene silencing - The next opportunities for capsid proof of concept lie with the Friedreich's ataxia and GBA programs, which are partnered with Neurocrine [52][53]. Question: Comparison of ALPL shuttle to other shuttles - The ALPL shuttle may have advantages over TfR-based shuttles, particularly regarding safety and distribution [149][150]. Question: Future indications for tau silencing program - The company intends to focus on Alzheimer's disease first, given the extensive knowledge of its natural history and measurement techniques [114][118].

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer and Chief of Staff to the CEO Alfred Sandrock - President and Chief Executive Officer Toby Ferguson - Chief Medical Officer Todd Carter - Chief Scientific Officer Nathan Jorgensen - Chief Financial Officer Conference Call Participants Jack Allen - Robert W. Baird Phil Nadeau - TD Cowen Pete Stavropoulos - Cantor Fitzgerald Lili Nsongo - Le ...

Group 1 - Voyager Therapeutics reported a quarterly loss of $0.59 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.35, and a significant decline from earnings of $1.25 per share a year ago, indicating an earnings surprise of -68.57% [1] - The company posted revenues of $6.28 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 68.81%, and a sharp decline from year-ago revenues of $90.06 million [2] - Voyager Therapeutics shares have declined approximately 26.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.5% [3] Group 2 - The earnings outlook for Voyager Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.37 on revenues of $18.69 million, and for the current fiscal year at -$1.59 on revenues of $88.9 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable industry outlook [8]